Gilead ex­pands its big bet on Ar­cus, mov­ing in­to in­flam­ma­tion in large new col­lab­o­ra­tion

Gilead and Ar­cus are ex­pand­ing their al­ready sig­nif­i­cant part­ner­ship, adding in­flam­ma­tion tar­gets to what was al­ready one of the biggest col­lab­o­ra­tion deals in the biotech world.

In 2020, the com­pa­nies an­nounced a 10-year agree­ment to go af­ter can­cer tar­gets that came with a $175 mil­lion up­front, a $200 mil­lion eq­ui­ty in­vest­ment and as much as $1.6 bil­lion in mile­stone pay­ments. That deal made Gilead a de­vel­op­ment and com­mer­cial part­ner on Ar­cus’s pro­grams, in­clud­ing its close­ly-watched TIG­IT can­di­date, with an op­tion to pay $150 mil­lion per mol­e­cule for fu­ture can­di­dates.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.